All Releases
 |
Arena Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
Mar 18, 2010
|
8.3 KB |
|
| |
SAN DIEGO, March 18, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florid...
|
|
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2009 Financial Results
Mar 12, 2010
|
20.2 KB |
|
| |
SAN DIEGO, March 12, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2009.
Arena reported a lower net loss allocable to common stockholders in the fourth quarter of 2009 of $29.8 million, or $0.32 per share, compared to ...
|
|
Arena Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Mar 8, 2010
|
8.3 KB |
|
| |
SAN DIEGO, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Cowen and Company 30th Annual Health Care Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time) at the Boston Marriott Copley Place in Bosto...
|
|
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 12, 2010
Mar 8, 2010
|
8.5 KB |
|
| |
SAN DIEGO, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Friday, March 12, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hof...
|
|
Arena Pharmaceuticals Receives PDUFA Date for Lorcaserin NDA
Feb 26, 2010
|
9.8 KB |
|
| |
SAN DIEGO, Feb. 26, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA ...
|
|
Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing
Feb 24, 2010
|
9.6 KB |
|
| |
SAN DIEGO, Feb. 24, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the U...
|
|
Arena Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Feb 4, 2010
|
8.2 KB |
|
| |
SAN DIEGO, Feb. 4, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief...
|
|
Arena Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Jan 4, 2010
|
8.4 KB |
|
| |
SAN DIEGO, Jan 04, 2010 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that the company is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2010 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Fra...
|
|
Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
Dec 23, 2009
|
8.6 KB |
|
| |
SAN DIEGO, Dec 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Ar...
|
|
Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
Dec 22, 2009
|
9.9 KB |
|
| |
SAN DIEGO, Dec 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss a...
|
|
Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential
Dec 10, 2009
|
10.0 KB |
|
| |
SAN DIEGO, Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial dem...
|
|
Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Nov 24, 2009
|
8.4 KB |
|
| |
SAN DIEGO, Nov 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that the company is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the New York Palace Hotel in New York City. Ja...
|
|
Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
Nov 9, 2009
|
17.4 KB |
|
| |
SAN DIEGO, Nov 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2009.
Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net l...
|
|
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
Nov 4, 2009
|
8.7 KB |
|
| |
SAN DIEGO, Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report third quarter 2009 financial results after the NASDAQ Global Market closes on Monday, November 9, 2009. The next morning, November 10, 2009, Jack Lief, Arena's President and Chief Executive Officer, and...
|
|
New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life
Oct 27, 2009
|
16.7 KB |
|
| |
WASHINGTON, Oct 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and qua...
|
|
Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Oct 25, 2009
|
14.8 KB |
|
| |
WASHINGTON, Oct 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that data from the pivotal BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) Phase 3 trial demonstrate lorcaserin significantly increased excess weight loss, improved markers of cardiovasc...
|
|
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Oct 22, 2009
|
8.6 KB |
|
| |
SAN DIEGO, Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that the company is scheduled to provide an overview of the company at two upcoming investor conferences:
-- BIOCOM Investor Conference
Presentation: Tuesday, October 27, 2009 at 3:30 p.m. Eastern Time
...
|
|
Arena Pharmaceuticals' Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Oct 12, 2009
|
12.3 KB |
|
| |
SAN DIEGO, Oct 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.
The line-up includes a late-breaking abstract oral presentation ...
|
|
Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Sep 18, 2009
|
8.2 KB |
|
| |
SAN DIEGO, Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the UBS Global Life Sciences Conference on September 23, 2009 at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Jack Lief, Aren...
|
|
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Sep 18, 2009
|
21.5 KB |
|
| |
SAN DIEGO, Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today positive, highly significant top-line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial. BLOSSOM confirms the results previously reported for the BLOOM (Behavi...
|
|
|
